Reconsidering the Use of Minocycline in the Preliminary Treatment Regime of Rheumatoid Arthritis
Identifieur interne : 000939 ( Pmc/Corpus ); précédent : 000938; suivant : 000940Reconsidering the Use of Minocycline in the Preliminary Treatment Regime of Rheumatoid Arthritis
Auteurs :Source :
- Cureus [ 2168-8184 ] ; ????.
Abstract
Strong epidemiologic, clinical, and basic science studies have identified a number of factors that may lead to rheumatoid arthritis (RA) onset and progression, particularly involving the complex interplay between genomics, environmental risk factors, the breakdown of immune self-tolerance, and microbiome dysbiosis. A chronic state of inflammation established by infectious agents has long been suspected to set the stage for the development of RA. The purpose of this article is to review the contribution of the gut, lung, and oral microbiomes to the pathogenesis of RA and consider the importance of supplementing the preliminary treatment regime of RA patients with antibiotics, in particular, minocycline. Minocycline has been used in the treatment of RA due to its bacteriostatic, as well as immunomodulatory and anti-inflammatory properties. Ultimately, a short course of antibiotic treatment with minocycline may eliminate pathogenic organisms contributing to the development and progression of RA.
Url:
DOI: 10.7759/cureus.5351
PubMed: 31608186
PubMed Central: 6783212
Links to Exploration step
PMC:6783212Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reconsidering the Use of Minocycline in the Preliminary Treatment Regime of Rheumatoid Arthritis</title></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31608186</idno><idno type="pmc">6783212</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783212</idno><idno type="RBID">PMC:6783212</idno><idno type="doi">10.7759/cureus.5351</idno><date when="????">????</date><idno type="wicri:Area/Pmc/Corpus">000939</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000939</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Reconsidering the Use of Minocycline in the Preliminary Treatment Regime of Rheumatoid Arthritis</title></analytic><series><title level="j">Cureus</title><idno type="eISSN">2168-8184</idno><imprint><date when="????">????</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Strong epidemiologic, clinical, and basic science studies have identified a number of factors that may lead to rheumatoid arthritis (RA) onset and progression, particularly involving the complex interplay between genomics, environmental risk factors, the breakdown of immune self-tolerance, and microbiome dysbiosis. A chronic state of inflammation established by infectious agents has long been suspected to set the stage for the development of RA. The purpose of this article is to review the contribution of the gut, lung, and oral microbiomes to the pathogenesis of RA and consider the importance of supplementing the preliminary treatment regime of RA patients with antibiotics, in particular, minocycline. Minocycline has been used in the treatment of RA due to its bacteriostatic, as well as immunomodulatory and anti-inflammatory properties. Ultimately, a short course of antibiotic treatment with minocycline may eliminate pathogenic organisms contributing to the development and progression of RA. </p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Firestein, Gs" uniqKey="Firestein G">GS Firestein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hunter, Tm" uniqKey="Hunter T">TM Hunter</name></author><author><name sortKey="Boytsov, Nn" uniqKey="Boytsov N">NN Boytsov</name></author><author><name sortKey="Zhang, X" uniqKey="Zhang X">X Zhang</name></author><author><name sortKey="Schroeder, K" uniqKey="Schroeder K">K Schroeder</name></author><author><name sortKey="Michaud, K" uniqKey="Michaud K">K Michaud</name></author><author><name sortKey="Araujo, Ab" uniqKey="Araujo A">AB Araujo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Turesson, C" uniqKey="Turesson C">C Turesson</name></author><author><name sortKey="O Fallon, Wm" uniqKey="O Fallon W">WM O'Fallon</name></author><author><name sortKey="Crowson, Cs" uniqKey="Crowson C">CS Crowson</name></author><author><name sortKey="Gabriel, Se" uniqKey="Gabriel S">SE Gabriel</name></author><author><name sortKey="Matteson, El" uniqKey="Matteson E">EL Matteson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Der Woude, D" uniqKey="Van Der Woude D">D van der Woude</name></author><author><name sortKey="Alemayehu, Wg" uniqKey="Alemayehu W">WG Alemayehu</name></author><author><name sortKey="Verduijn, W" uniqKey="Verduijn W">W Verduijn</name></author><author><name sortKey="De Vries, Rr" uniqKey="De Vries R">RR de Vries</name></author><author><name sortKey="Houwing Duistermaat, Jj" uniqKey="Houwing Duistermaat J">JJ Houwing-Duistermaat</name></author><author><name sortKey="Huizinga, Tw" uniqKey="Huizinga T">TW Huizinga</name></author><author><name sortKey="Toes, Re" uniqKey="Toes R">RE Toes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Horta Baas, G" uniqKey="Horta Baas G">G Horta-Baas</name></author><author><name sortKey="Romero Figueroa, Mds" uniqKey="Romero Figueroa M">MDS Romero-Figueroa</name></author><author><name sortKey="Montiel Jarquin, Aj" uniqKey="Montiel Jarquin A">AJ Montiel-Jarquín</name></author><author><name sortKey="Pizano Zarate, Ml" uniqKey="Pizano Zarate M">ML Pizano-Zárate</name></author><author><name sortKey="Garcia Mena, J" uniqKey="Garcia Mena J">J García-Mena</name></author><author><name sortKey="Ramirez Duran, N" uniqKey="Ramirez Duran N">N Ramírez-Durán</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lourido, L" uniqKey="Lourido L">L Lourido</name></author><author><name sortKey="Blanco, Fj" uniqKey="Blanco F">FJ Blanco</name></author><author><name sortKey="Ruiz Romero, C" uniqKey="Ruiz Romero C">C Ruiz-Romero</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Scher, Ju" uniqKey="Scher J">JU Scher</name></author><author><name sortKey="Joshua, V" uniqKey="Joshua V">V Joshua</name></author><author><name sortKey="Artacho, A" uniqKey="Artacho A">A Artacho</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bennike, Tb" uniqKey="Bennike T">TB Bennike</name></author><author><name sortKey="Ellingsen, T" uniqKey="Ellingsen T">T Ellingsen</name></author><author><name sortKey="Glerup, H" uniqKey="Glerup H">H Glerup</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Scher, Ju" uniqKey="Scher J">JU Scher</name></author><author><name sortKey="Sczesnak, A" uniqKey="Sczesnak A">A Sczesnak</name></author><author><name sortKey="Longman, Rs" uniqKey="Longman R">RS Longman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Scher, Ju" uniqKey="Scher J">JU Scher</name></author><author><name sortKey="Ubeda, C" uniqKey="Ubeda C">C Ubeda</name></author><author><name sortKey="Equinda, M" uniqKey="Equinda M">M Equinda</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mikuls, Tr" uniqKey="Mikuls T">TR Mikuls</name></author><author><name sortKey="Payne, Jb" uniqKey="Payne J">JB Payne</name></author><author><name sortKey="Reinhardt, Ra" uniqKey="Reinhardt R">RA Reinhardt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Smit, M" uniqKey="De Smit M">M de Smit</name></author><author><name sortKey="Westra, J" uniqKey="Westra J">J Westra</name></author><author><name sortKey="Vissink, A" uniqKey="Vissink A">A Vissink</name></author><author><name sortKey="Doornbos Van Der Meer, B" uniqKey="Doornbos Van Der Meer B">B Doornbos-van der Meer</name></author><author><name sortKey="Brouwer, E" uniqKey="Brouwer E">E Brouwer</name></author><author><name sortKey="Van Winkelhoff, Aj" uniqKey="Van Winkelhoff A">AJ van Winkelhoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheng, Z" uniqKey="Cheng Z">Z Cheng</name></author><author><name sortKey="Meade, J" uniqKey="Meade J">J Meade</name></author><author><name sortKey="Mankia, K" uniqKey="Mankia K">K Mankia</name></author><author><name sortKey="Emery, P" uniqKey="Emery P">P Emery</name></author><author><name sortKey="Devine, Da" uniqKey="Devine D">DA Devine</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Scher, Ju" uniqKey="Scher J">JU Scher</name></author><author><name sortKey="Abramson, Sb" uniqKey="Abramson S">SB Abramson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cruz, Fm" uniqKey="Cruz F">FM Cruz</name></author><author><name sortKey="Colbert, Jd" uniqKey="Colbert J">JD Colbert</name></author><author><name sortKey="Merino, E" uniqKey="Merino E">E Merino</name></author><author><name sortKey="Kriegsman, Ba" uniqKey="Kriegsman B">BA Kriegsman</name></author><author><name sortKey="Rock, Kl" uniqKey="Rock K">KL Rock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yu, Hc" uniqKey="Yu H">HC Yu</name></author><author><name sortKey="Lu, Mc" uniqKey="Lu M">MC Lu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schellekens, Ga" uniqKey="Schellekens G">GA Schellekens</name></author><author><name sortKey="Visser, H" uniqKey="Visser H">H Visser</name></author><author><name sortKey="De Jong, Ba" uniqKey="De Jong B">BA de Jong</name></author><author><name sortKey="Van Den Hoogen, Fh" uniqKey="Van Den Hoogen F">FH van den Hoogen</name></author><author><name sortKey="Hazes, Jm" uniqKey="Hazes J">JM Hazes</name></author><author><name sortKey="Breedveld, Fc" uniqKey="Breedveld F">FC Breedveld</name></author><author><name sortKey="Van Venrooij, Wj" uniqKey="Van Venrooij W">WJ van Venrooij</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Torow, N" uniqKey="Torow N">N Torow</name></author><author><name sortKey="Marsland, Bj" uniqKey="Marsland B">BJ Marsland</name></author><author><name sortKey="Hornef, Mw" uniqKey="Hornef M">MW Hornef</name></author><author><name sortKey="Gollwitzer, Es" uniqKey="Gollwitzer E">ES Gollwitzer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Den Broek, Mf" uniqKey="Van Den Broek M">MF van den Broek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lehman, Tj" uniqKey="Lehman T">TJ Lehman</name></author><author><name sortKey="Allen, Jb" uniqKey="Allen J">JB Allen</name></author><author><name sortKey="Plotz, Ph" uniqKey="Plotz P">PH Plotz</name></author><author><name sortKey="Wilder, Rl" uniqKey="Wilder R">RL Wilder</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu, Hj" uniqKey="Wu H">HJ Wu</name></author><author><name sortKey="Ivanov, Ii" uniqKey="Ivanov I">II Ivanov</name></author><author><name sortKey="Darce, J" uniqKey="Darce J">J Darce</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maeda, Y" uniqKey="Maeda Y">Y Maeda</name></author><author><name sortKey="Kurakawa, T" uniqKey="Kurakawa T">T Kurakawa</name></author><author><name sortKey="Umemoto, E" uniqKey="Umemoto E">E Umemoto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Costenbader, Kh" uniqKey="Costenbader K">KH Costenbader</name></author><author><name sortKey="Karlson, Ew" uniqKey="Karlson E">EW Karlson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcgraw, Wt" uniqKey="Mcgraw W">WT McGraw</name></author><author><name sortKey="Potempa, J" uniqKey="Potempa J">J Potempa</name></author><author><name sortKey="Farley, D" uniqKey="Farley D">D Farley</name></author><author><name sortKey="Travis, J" uniqKey="Travis J">J Travis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Konig, Mf" uniqKey="Konig M">MF Konig</name></author><author><name sortKey="Abusleme, L" uniqKey="Abusleme L">L Abusleme</name></author><author><name sortKey="Reinholdt, J" uniqKey="Reinholdt J">J Reinholdt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chhibber Goel, J" uniqKey="Chhibber Goel J">J Chhibber-Goel</name></author><author><name sortKey="Singhal, V" uniqKey="Singhal V">V Singhal</name></author><author><name sortKey="Bhowmik, D" uniqKey="Bhowmik D">D Bhowmik</name></author><author><name sortKey="Vivek, R" uniqKey="Vivek R">R Vivek</name></author><author><name sortKey="Parakh, N" uniqKey="Parakh N">N Parakh</name></author><author><name sortKey="Bhargava, B" uniqKey="Bhargava B">B Bhargava</name></author><author><name sortKey="Sharma, A" uniqKey="Sharma A">A Sharma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Song, S" uniqKey="Song S">S Song</name></author><author><name sortKey="Yu, Y" uniqKey="Yu Y">Y Yu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chopra, I" uniqKey="Chopra I">I Chopra</name></author><author><name sortKey="Roberts, M" uniqKey="Roberts M">M Roberts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Agwuh, Kn" uniqKey="Agwuh K">KN Agwuh</name></author><author><name sortKey="Macgowan, A" uniqKey="Macgowan A">A MacGowan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pruzanski, W" uniqKey="Pruzanski W">W Pruzanski</name></author><author><name sortKey="Greenwald, Ra" uniqKey="Greenwald R">RA Greenwald</name></author><author><name sortKey="Street, Lp" uniqKey="Street L">LP Street</name></author><author><name sortKey="Laliberte, F" uniqKey="Laliberte F">F Laliberte</name></author><author><name sortKey="Stefanski, E" uniqKey="Stefanski E">E Stefanski</name></author><author><name sortKey="Vadas, P" uniqKey="Vadas P">P Vadas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Greenwald, Ra" uniqKey="Greenwald R">RA Greenwald</name></author><author><name sortKey="Moak, Sa" uniqKey="Moak S">SA Moak</name></author><author><name sortKey="Ramamurthy, Ns" uniqKey="Ramamurthy N">NS Ramamurthy</name></author><author><name sortKey="Golub, Lm" uniqKey="Golub L">LM Golub</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wasil, M" uniqKey="Wasil M">M Wasil</name></author><author><name sortKey="Halliwell, B" uniqKey="Halliwell B">B Halliwell</name></author><author><name sortKey="Moorhouse, Cp" uniqKey="Moorhouse C">CP Moorhouse</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kloppenburg, M" uniqKey="Kloppenburg M">M Kloppenburg</name></author><author><name sortKey="Breedveld, Fc" uniqKey="Breedveld F">FC Breedveld</name></author><author><name sortKey="Terwiel, Jp" uniqKey="Terwiel J">JP Terwiel</name></author><author><name sortKey="Mallee, C" uniqKey="Mallee C">C Mallee</name></author><author><name sortKey="Dijkmans, Ba" uniqKey="Dijkmans B">BA Dijkmans</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tilley, Bc" uniqKey="Tilley B">BC Tilley</name></author><author><name sortKey="Alarc N, Gs" uniqKey="Alarc N G">GS Alarcón</name></author><author><name sortKey="Heyse, Sp" uniqKey="Heyse S">SP Heyse</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="O Dell, Jr" uniqKey="O Dell J">JR O'Dell</name></author><author><name sortKey="Haire, Ce" uniqKey="Haire C">CE Haire</name></author><author><name sortKey="Palmer, W" uniqKey="Palmer W">W Palmer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="O Dell, Jr" uniqKey="O Dell J">JR O'Dell</name></author><author><name sortKey="Blakely, Kw" uniqKey="Blakely K">KW Blakely</name></author><author><name sortKey="Mallek, Ja" uniqKey="Mallek J">JA Mallek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Langevitz, P" uniqKey="Langevitz P">P Langevitz</name></author><author><name sortKey="Bank, I" uniqKey="Bank I">I Bank</name></author><author><name sortKey="Zemer, D" uniqKey="Zemer D">D Zemer</name></author><author><name sortKey="Book, M" uniqKey="Book M">M Book</name></author><author><name sortKey="Pras, M" uniqKey="Pras M">M Pras</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Breedveld, Fc" uniqKey="Breedveld F">FC Breedveld</name></author><author><name sortKey="Dijkmans, Ba" uniqKey="Dijkmans B">BA Dijkmans</name></author><author><name sortKey="Mattie, H" uniqKey="Mattie H">H Mattie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Skinner, M" uniqKey="Skinner M">M Skinner</name></author><author><name sortKey="Cathcart, Es" uniqKey="Cathcart E">ES Cathcart</name></author><author><name sortKey="Mills, Ja" uniqKey="Mills J">JA Mills</name></author><author><name sortKey="Pinals, Rs" uniqKey="Pinals R">RS Pinals</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Der Laan, W" uniqKey="Van Der Laan W">W van der Laan</name></author><author><name sortKey="Molenaar, E" uniqKey="Molenaar E">E Molenaar</name></author><author><name sortKey="Ronday, K" uniqKey="Ronday K">K Ronday</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pillemer, S" uniqKey="Pillemer S">S Pillemer</name></author><author><name sortKey="Gulko, P" uniqKey="Gulko P">P Gulko</name></author><author><name sortKey="Ligier, S" uniqKey="Ligier S">S Ligier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="St Clair, Ew" uniqKey="St Clair E">EW St. Clair</name></author><author><name sortKey="Wilkinson, We" uniqKey="Wilkinson W">WE Wilkinson</name></author><author><name sortKey="Pisetsky, Ds" uniqKey="Pisetsky D">DS Pisetsky</name></author><author><name sortKey="Sexton, Dj" uniqKey="Sexton D">DJ Sexton</name></author><author><name sortKey="Drew, R" uniqKey="Drew R">R Drew</name></author><author><name sortKey="Kraus, Vb" uniqKey="Kraus V">VB Kraus</name></author><author><name sortKey="Greenwald, Ra" uniqKey="Greenwald R">RA Greenwald</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stone, M" uniqKey="Stone M">M Stone</name></author><author><name sortKey="Fortin, Pr" uniqKey="Fortin P">PR Fortin</name></author><author><name sortKey="Pacheco Tena, C" uniqKey="Pacheco Tena C">C Pacheco-Tena</name></author><author><name sortKey="Inman, Rd" uniqKey="Inman R">RD Inman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mukherjee, A" uniqKey="Mukherjee A">A Mukherjee</name></author><author><name sortKey="Jantsch, V" uniqKey="Jantsch V">V Jantsch</name></author><author><name sortKey="Khan, R" uniqKey="Khan R">R Khan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oettinger Barak, O" uniqKey="Oettinger Barak O">O Oettinger-Barak</name></author><author><name sortKey="Dashper, Sg" uniqKey="Dashper S">SG Dashper</name></author><author><name sortKey="Catmull, Dv" uniqKey="Catmull D">DV Catmull</name></author><author><name sortKey="Adams, Gg" uniqKey="Adams G">GG Adams</name></author><author><name sortKey="Sela, Mn" uniqKey="Sela M">MN Sela</name></author><author><name sortKey="Machtei, Ee" uniqKey="Machtei E">EE Machtei</name></author><author><name sortKey="Reynolds, Ec" uniqKey="Reynolds E">EC Reynolds</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, Cj" uniqKey="Smith C">CJ Smith</name></author><author><name sortKey="Sayles, H" uniqKey="Sayles H">H Sayles</name></author><author><name sortKey="Mikuls, Tr" uniqKey="Mikuls T">TR Mikuls</name></author><author><name sortKey="Michaud, K" uniqKey="Michaud K">K Michaud</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Elkayam, O" uniqKey="Elkayam O">O Elkayam</name></author><author><name sortKey="Yaron, M" uniqKey="Yaron M">M Yaron</name></author><author><name sortKey="Caspi, D" uniqKey="Caspi D">D Caspi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tariq, R" uniqKey="Tariq R">R Tariq</name></author><author><name sortKey="Cho, J" uniqKey="Cho J">J Cho</name></author><author><name sortKey="Kapoor, S" uniqKey="Kapoor S">S Kapoor</name></author><author><name sortKey="Orenstein, R" uniqKey="Orenstein R">R Orenstein</name></author><author><name sortKey="Singh, S" uniqKey="Singh S">S Singh</name></author><author><name sortKey="Pardi, Ds" uniqKey="Pardi D">DS Pardi</name></author><author><name sortKey="Khanna, S" uniqKey="Khanna S">S Khanna</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Friedman, Gd" uniqKey="Friedman G">GD Friedman</name></author><author><name sortKey="Oestreicher, N" uniqKey="Oestreicher N">N Oestreicher</name></author><author><name sortKey="Chan, J" uniqKey="Chan J">J Chan</name></author><author><name sortKey="Quesenberry Cp, Jr" uniqKey="Quesenberry Cp J">Jr Quesenberry CP</name></author><author><name sortKey="Udaltsova, N" uniqKey="Udaltsova N">N Udaltsova</name></author><author><name sortKey="Habel, La" uniqKey="Habel L">LA Habel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boursi, B" uniqKey="Boursi B">B Boursi</name></author><author><name sortKey="Mamtani, R" uniqKey="Mamtani R">R Mamtani</name></author><author><name sortKey="Haynes, K" uniqKey="Haynes K">K Haynes</name></author><author><name sortKey="Yang, Yx" uniqKey="Yang Y">YX Yang</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31608186</article-id><article-id pub-id-type="pmc">6783212</article-id><article-id pub-id-type="doi">10.7759/cureus.5351</article-id><article-categories><subj-group subj-group-type="heading"><subject>Allergy/Immunology</subject></subj-group><subj-group><subject>Infectious Disease</subject></subj-group><subj-group><subject>Rheumatology</subject></subj-group></article-categories><title-group><article-title>Reconsidering the Use of Minocycline in the Preliminary Treatment Regime of Rheumatoid Arthritis</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Heydari-Kamjani</surname><given-names>Milad</given-names></name><xref ref-type="aff" rid="aff-177573">1</xref></contrib><contrib contrib-type="author"><name><surname>Demory Beckler</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="aff-177572">2</xref></contrib><contrib contrib-type="author"><name><surname>Kesselman</surname><given-names>Marc M</given-names></name><xref ref-type="aff" rid="aff-170370">3</xref></contrib></contrib-group><aff id="aff-177573"><label>1</label> Osteopathic Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, USA</aff><aff id="aff-177572"><label>2</label> Immunology, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, USA</aff><aff id="aff-170370"><label>3</label> Rheumatology, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, USA</aff><author-notes><corresp id="cor1">Milad Heydari-Kamjani <email>miladheydarik@gmail.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>8</day><month>8</month><year>2019</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>8</month><year>2019</year></pub-date><volume>11</volume><issue>8</issue><elocation-id>e5351</elocation-id><history><date date-type="received"><day>6</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>8</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>Copyright © 2019, Heydari-Kamjani et al.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Heydari-Kamjani et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/19619-reconsidering-the-use-of-minocycline-in-the-preliminary-treatment-regime-of-rheumatoid-arthritis">This article is available from https://www.cureus.com/articles/19619-reconsidering-the-use-of-minocycline-in-the-preliminary-treatment-regime-of-rheumatoid-arthritis</self-uri><abstract><p>Strong epidemiologic, clinical, and basic science studies have identified a number of factors that may lead to rheumatoid arthritis (RA) onset and progression, particularly involving the complex interplay between genomics, environmental risk factors, the breakdown of immune self-tolerance, and microbiome dysbiosis. A chronic state of inflammation established by infectious agents has long been suspected to set the stage for the development of RA. The purpose of this article is to review the contribution of the gut, lung, and oral microbiomes to the pathogenesis of RA and consider the importance of supplementing the preliminary treatment regime of RA patients with antibiotics, in particular, minocycline. Minocycline has been used in the treatment of RA due to its bacteriostatic, as well as immunomodulatory and anti-inflammatory properties. Ultimately, a short course of antibiotic treatment with minocycline may eliminate pathogenic organisms contributing to the development and progression of RA. </p></abstract><kwd-group kwd-group-type="author"><kwd>microbiome dysbiosis</kwd><kwd>rheumatoid arthritis</kwd><kwd>antibiotics</kwd><kwd>minocycline</kwd></kwd-group></article-meta><notes><p content-type="disclaimer">The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.</p></notes></front><body><sec sec-type="intro"><title>Introduction and background</title><p>Rheumatoid arthritis (RA) is a common autoimmune condition that is present in approximately 1% of the world's population [<xref rid="REF1" ref-type="bibr">1</xref>]. The prevalence of RA in the United States is estimated to affect approximately 1.28 - 1.36 million adults [<xref rid="REF2" ref-type="bibr">2</xref>]. Patients with RA typically present with symmetric polyarthritis affecting smalls joints of the hands and feet [<xref rid="REF1" ref-type="bibr">1</xref>], but patients can also develop extra-articular manifestations, including diabetes, osteoporosis, vasculitis, interstitial lung disease, and cardiovascular disease [<xref rid="REF3" ref-type="bibr">3</xref>]. The pathogenesis of RA remains unclear despite inroads into understanding the underlying mechanisms of the disease activity. Strong epidemiologic, clinical, and basic science studies have identified a number of factors that may lead to disease onset and progression, particularly involving the complex interplay between genomics, environmental risk factors, breakdown of immune self-tolerance, and microbiome dysbiosis [<xref rid="REF4" ref-type="bibr">4</xref>].</p><p>A chronic state of inflammation established by infectious agents has long been suspected to set the stage for the development of RA. Recent studies have shown an association between the gut, lung, and oral microbiomes and their contribution to the pathogenesis of RA [<xref rid="REF5" ref-type="bibr">5</xref>-<xref rid="REF13" ref-type="bibr">13</xref>]. Under homeostatic conditions, the resident microorganisms at these mucosal sites establish a mutualistic relationship amongst themselves and with their host. When there is a disruption in the diversity of these organisms, a prolonged inflammatory response can occur [<xref rid="REF5" ref-type="bibr">5</xref>]. Specifically, particular bacterial products, such as pathogen-associated molecular patterns (PAMPS), can bind to toll-like-receptors (TLR) on the surface of epithelial cells and stimulate a signal transduction cascade that results in upregulation of proinflammatory cytokines, including interleukin-1, interleukin-6, and tumor necrosis factor-alpha [<xref rid="REF14" ref-type="bibr">14</xref>]. In addition, dendritic cells acting as antigen-presenting cells (APC) can display bacterial-induced citrullinated peptides on their major histocompatibility (MHC) complex class II molecules [<xref rid="REF15" ref-type="bibr">15</xref>]. Protein citrullination is a post-translational modification process that occurs widely in cell differentiation, inflammation, and apoptosis [<xref rid="REF16" ref-type="bibr">16</xref>]. This physiological process requires the presence of peptidyl-arginine deiminase (PAD) that converts C-terminal arginine residue (positive charge) to citrulline molecule (neutral charge), which creates a new epitope that is immunogenic in RA patients due to loss of self-tolerance [<xref rid="REF16" ref-type="bibr">16</xref>]. Currently, the presence of anti-citrullinated protein antibodies (ACPAs) remains the most specific serological marker used in the diagnosis of RA [<xref rid="REF17" ref-type="bibr">17</xref>]. Given that a subset of RA patients are genetic carriers of human leukocyte antigen (HLA)-DR alleles which encodes the MHC complex, it is plausible to hypothesize that a mutation in the MHC class II cells, together with microbiome dysbiosis, may set the stage for the development of RA [<xref rid="REF1" ref-type="bibr">1</xref>]. Consequently, the gut, lung, and oral microbiomes likely play an important role in determining the overall tone of the immune system at these mucosal sites and are currently the leading targets for future interventions in RA [<xref rid="REF18" ref-type="bibr">18</xref>]. The purpose of this article is to discuss the potential contributions of the gut, lung, and oral microbiomes to the pathogenesis of RA and to consider the addition of minocycline to the preliminary treatment regime of RA in efforts to eliminate pathogenic bacteria that may contribute to the development and progression of RA. </p></sec><sec sec-type="review"><title>Review</title><p>The role of gut microbiota in RA</p><p>The potential role of the gut microbiota in the development of RA is supported by studies in animal models and analyses of the intestinal microbiome. Specifically, murine arthritis models have shown that injection of <italic>Streptococcus pyogenes </italic>and <italic>Lactobacillus casei </italic>cell wall components can induce erosive polyarthritis [<xref rid="REF19" ref-type="bibr">19</xref>-<xref rid="REF20" ref-type="bibr">20</xref>]. Similarly, gnotobiotic mice (germ-free mice) inoculated with segmental filamentous bacteria (SFB) results in the production of autoantibodies and development of erosive arthritis [<xref rid="REF21" ref-type="bibr">21</xref>]. Furthermore, colonic tissue analysis of RA patients has identified 21 citrullinated peptides [<xref rid="REF8" ref-type="bibr">8</xref>]. In particular, three of these citrullinated proteins (vimentin, fibrinogen-alpha, and actin) are known targets for ACPA, supporting the hypothesis that a breakdown in self-tolerance at the colonic mucosal site could initiate ACPA production in RA patients [<xref rid="REF8" ref-type="bibr">8</xref>]. Lastly, fecal analysis of RA patients reveals a difference in the composition of the gut microbiome when compared to healthy individuals. For example, early RA patients appear to have a higher abundance of <italic>Prevotella copri (P. copri) </italic>[<xref rid="REF9" ref-type="bibr">9</xref>, <xref rid="REF22" ref-type="bibr">22</xref>]. <italic>P. copri </italic>has been shown to induce CD4+ T-cells to differentiate into T-helper 17 (Th17) cells resulting in the production of proinflammatory cytokines and activation of B cells with consequent antibody production [<xref rid="REF9" ref-type="bibr">9</xref>, <xref rid="REF22" ref-type="bibr">22</xref>]. Collectively, these findings strengthen the hypothesis that the gut microbiome may play a role in the development and progression of RA.</p><p>The role of lung microbiota in RA</p><p>The lung microbiome is another suspected mucosal site to play a role in the pathogenesis of RA. The evidence behind this idea comes from a proteomic study where two citrullinated vimentin peptides have been identified in the bronchial and synovial tissues of patients with RA [<xref rid="REF6" ref-type="bibr">6</xref>]. In addition, before the onset of arthritis, ACPAs are present in the sputum of ACPA-positive RA patients; however, these antibodies are not present in healthy controls [<xref rid="REF5" ref-type="bibr">5</xref>]. Similarly, high-resolution computed tomography has shown lung parenchymal abnormality prior to the onset of the disease in ACPA-positive patients. Although the precise mechanism is unclear, smoking, a well-known risk factor for RA, has been shown to increase the citrullination of proteins by upregulating PAD [<xref rid="REF23" ref-type="bibr">23</xref>]. As a result, citrullinated proteins can become auto-antigens in a genetically susceptible patient and may predispose an individual to develop RA.</p><p>The role of oral microbiota in RA</p><p>The oral microbiome has received a tremendous amount of attention due to the association identified between periodontitis (PD) and RA [<xref rid="REF10" ref-type="bibr">10</xref>-<xref rid="REF13" ref-type="bibr">13</xref>]. PD is an infectious disease caused by various oral anaerobic bacteria resulting in the destruction of the tooth-supporting structures. Specifically, two periodontal pathogens, <italic>Porphyromonas gingivalis </italic>(Pg) and <italic>Aggregatibacter actinomycetemcomitans</italic> (Aa), have been shown to produce citrullinated peptides and have been suggested to contribute to the pathogenesis of RA. Pg is gram-negative obligate anaerobic bacteria that express bacterial PAD, which is known to directly citrullinate human protein peptides at the arginine residue [<xref rid="REF24" ref-type="bibr">24</xref>]. Aa is gram-negative facultative anaerobic bacteria that express leukotoxin A (LtxA), which destabilizes cell membrane integrity by forming pores, ultimately leading to unregulated calcium influx [<xref rid="REF25" ref-type="bibr">25</xref>]. In neutrophils, an influx of calcium ions results in the activation of endogenous PAD, leading to indirect hypercitrullination of proteins. Combined, these examples highlight the similarities in the pathogenesis of PD and RA and provide a link between the human microbiome and the development of RA.</p><p>The role of tetracyclines in RA</p><p>The vast amount of research analyzing the gut, lung, and oral microbiomes have helped portray a convincing picture that microbiome dysbiosis at these mucosal sites can contribute to a chronic inflammatory state, the underlying mechanism in RA, and its two well-known comorbidities, coronary artery disease (CAD) [<xref rid="REF26" ref-type="bibr">26</xref>], and cancer [<xref rid="REF27" ref-type="bibr">27</xref>]. Given that treatment goals in RA are aimed to slow disease progression and reduce its associated comorbidities, we believe it is time to reevaluate and consider the importance of supplementing the preliminary treatment regime of RA patients with antibiotics, in particular, minocycline. Ultimately, a short course of antibiotic treatment with minocycline may eliminate pathogenic organisms contributing to the development and progression of RA. </p><p>Tetracycline and its derivatives (minocycline and doxycycline) are a class of broad-spectrum antibiotic compounds that have in common a four-fused hydrocarbon ring. The distinguishing factors of these subclasses from one another are distinctive functional groups attached to different sites on the hydrocarbon backbone [<xref rid="REF28" ref-type="bibr">28</xref>]. These functional groups affect the pharmacokinetic properties of these antibiotics without altering their function [<xref rid="REF28" ref-type="bibr">28</xref>-<xref rid="REF29" ref-type="bibr">29</xref>]. Tetracyclines function as a bacteriostatic antibiotic by specifically binding to bacterial 30S ribosomal subunits, thus preventing bacterial protein synthesis [<xref rid="REF28" ref-type="bibr">28</xref>]. In addition to their bacteriostatic property, tetracyclines also have several inherent immunomodulatory properties [<xref rid="REF30" ref-type="bibr">30</xref>-<xref rid="REF32" ref-type="bibr">32</xref>]. Specifically, these drugs can inhibit phospholipase A-2, resulting in decreased production of arachidonic acid metabolites that are the key mediators of inflammation [<xref rid="REF30" ref-type="bibr">30</xref>]. They have antioxidant properties because they can act as scavengers of hypochlorous acid [<xref rid="REF32" ref-type="bibr">32</xref>]. Lastly, they have been shown to inhibit metalloproteinases which play a role in cartilage degradation [<xref rid="REF31" ref-type="bibr">31</xref>]. Given these properties and their potential in modulating RA-induced inflammation, joint destruction, and arthritis, a number of clinical trials assessing tetracycline use in the treatment of RA have been performed [<xref rid="REF33" ref-type="bibr">33</xref>-<xref rid="REF43" ref-type="bibr">43</xref>].</p><p>Clinical trials evaluating the therapeutic effects of tetracyclines</p><p>The tetracycline class of antibiotics has been widely studied in the treatment of RA, with varied outcomes and its use remaining controversial in clinical practice. Specifically, four double-blind randomized clinical trials have been published highlighting the significance of minocycline in the treatment of RA patients. The first study involved 80 long-term RA patients who did not benefit from more than one disease-modifying antirheumatic drug (DMARD) [<xref rid="REF33" ref-type="bibr">33</xref>]. Patients were treated with 200 mg of oral minocycline or a placebo in conjugation to their standard therapy for six months [<xref rid="REF33" ref-type="bibr">33</xref>]. Compared to the control group, the treatment group showed a statistical difference in laboratory parameters, such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and IgM rheumatoid factor (RF) levels [<xref rid="REF33" ref-type="bibr">33</xref>]. In a second study, 219 adults with active RA who had limited benefits using DMARDS were examined [<xref rid="REF34" ref-type="bibr">34</xref>]. Those patients were treated with 200 mg of oral minocycline or placebo for 48 weeks. The minocycline treatment group showed statistically significant improvement in joint swelling and joint tenderness, ESR, and RF levels. The last two studies were conducted by the Rheumatoid Arthritis Investigational Network (RAIN) Group [<xref rid="REF35" ref-type="bibr">35</xref>-<xref rid="REF36" ref-type="bibr">36</xref>]. Their first study involved 46 naive RA patients that were diagnosed for less than one year [<xref rid="REF35" ref-type="bibr">35</xref>]. Patients received 100 mg of oral minocycline twice daily for six months and were compared to the placebo group. The treatment group showed a statistically significant improvement in the morning stiffness, patient global status, and physician global status. In the second study by the RAIN Group, 60 RA patients with a duration of less than one year were randomized to receive 100 mg of oral minocycline twice daily or a placebo [<xref rid="REF36" ref-type="bibr">36</xref>]. All patients were on low-dose prednisone and were never treated with DMARDS. The patients treated with minocycline were more likely to achieve greater than 50% improvement in the American College of Rheumatology (ACR) criteria and did so while receiving less prednisone. In addition to the four double-blind studies, two open-label trials showed similar positive results when evaluating the efficacy of minocycline in the treatment of RA [<xref rid="REF37" ref-type="bibr">37</xref>-<xref rid="REF38" ref-type="bibr">38</xref>]. The first study included 18 RA patients who received 200 mg of oral minocycline daily for 48 weeks [<xref rid="REF37" ref-type="bibr">37</xref>]. The second study included 10 RA patients who received 400 mg of oral minocycline for 16 weeks [<xref rid="REF38" ref-type="bibr">38</xref>]. Both studies showed statistically significant improvement in the Disease Activity Score-28 (DAS-28). While minocycline showed some benefit, the combination of tetracycline [<xref rid="REF39" ref-type="bibr">39</xref>] and doxycycline [<xref rid="REF40" ref-type="bibr">40</xref>-<xref rid="REF42" ref-type="bibr">42</xref>] showed no benefit with studies demonstrating no statistically significant difference in reducing DAS-28 when comparing RA patients to those who received a placebo. These clinical trial studies were further analyzed by a meta-analysis highlighting that minocycline can significantly reduce the DAS-28 score in RA patients with no significant effect on radiographic progressions [<xref rid="REF43" ref-type="bibr">43</xref>]. Combined, these clinical trials suggest that tetracycline (in particular, minocycline) appears to be beneficial in reducing RA symptoms.</p><p>Previous clinical trials have analyzed the overall therapeutic effects of tetracycline in RA patients, but they did not differentiate whether it is through its bacteriostatic or immune-modulatory properties [<xref rid="REF33" ref-type="bibr">33</xref>-<xref rid="REF43" ref-type="bibr">43</xref>]. However, a recent case presentation demonstrated that a virulent strain of Aa initially led to subacute endocarditis, which later resulted in the development of early seropositive RA in a genetically susceptible individual [<xref rid="REF44" ref-type="bibr">44</xref>]. Perhaps more importantly, switching treatment options from immunosuppressive agents (methotrexate, prednisone, etanercept, leflunomide) to an antibacterial agent (intravenous ceftriaxone) for six months resolved the RA symptoms characterized by normal levels of CRP and ACPA [<xref rid="REF44" ref-type="bibr">44</xref>]. Although tetracyclines were not used in this particular case, they have shown in vitro to be effective against Aa JP2, the most virulent type of this bacteria [<xref rid="REF45" ref-type="bibr">45</xref>]. Given this, it may be plausible that using tetracyclines could have shown similar results. This case presentation further adds to the theory that microbiome dysbiosis in a genetically susceptible individual can result in the production of immunologic response to naïve peptides and set the stage for the development of RA. Therefore, we believe it is imperative for clinicians to assess for infection etiology as a source of chronic inflammation when a patient presents with symptoms of RA. Since the treatment goal is to slow disease progression and reduce its associated comorbidities, it is time to reevaluate the efficacy of antibiotics and consider their addition to the preliminary treatment regime of patients with RA. Ultimately, a short course of antibiotic treatment with minocycline may eliminate pathogenic organisms contributing to the development and progress of RA. </p><p>Side effects of tetracyclines</p><p>Minocycline is typically a well-tolerated antibiotic; however, common side effects can be seen in up to 18% of patients [<xref rid="REF46" ref-type="bibr">46</xref>]. These include photosensitivity, hyperpigmentation, dizziness, nausea, headache, tinnitus, diarrhea, and abdominal pain [<xref rid="REF46" ref-type="bibr">46</xref>]. There are several severe side effects of minocycline that are worth addressing. First, it has been reported that individuals with abnormal liver function may develop drug-induced lupus [<xref rid="REF47" ref-type="bibr">47</xref>]. However, upon discontinuation of the medication, the symptoms will spontaneously resolve with a few weeks to months. Second, there appears to be a lower risk of <italic>Clostridium difficile </italic>infection compared to clindamycin that has a well-known increased risk of infection [<xref rid="REF48" ref-type="bibr">48</xref>]. Third, the use of chronic tetracyclines may be associated with an increased risk of developing breast cancer in women or prostate cancer in men [<xref rid="REF49" ref-type="bibr">49</xref>-<xref rid="REF50" ref-type="bibr">50</xref>].</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Rheumatoid arthritis is an autoimmune condition that involves a complex interplay of multiple factors, including microbiome dysbiosis. The gut, lung, and oral microbiome dysbiosis may play a role in the pathogenesis of RA by contributing to a chronic inflammatory state. Given our current understanding of the microbiome, the addition of tetracyclines antibiotics, in particular, minocycline, may pose benefits through its bacteriostatic and immunomodulatory properties. Ultimately, a short course of antibiotic treatment with minocycline may eliminate pathogenic organisms contributing to the development and progression of RA. </p></sec></body><back><fn-group content-type="competing-interests"><fn fn-type="COI-statement"><p>The authors have declared that no competing interests exist.</p></fn></fn-group><ack><p>We would like to thank Beth Gilbert, Ed.D. for her assistance in editing this paper.</p></ack><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Evolving concepts of rheumatoid arthritis</article-title><source>Nature</source><person-group><name><surname>Firestein</surname><given-names>GS</given-names></name></person-group><fpage>356</fpage><lpage>361</lpage><volume>423</volume><year>2003</year><pub-id pub-id-type="pmid">12748655</pub-id></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014</article-title><source>Rheumatol Int</source><person-group><name><surname>Hunter</surname><given-names>TM</given-names></name><name><surname>Boytsov</surname><given-names>NN</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Schroeder</surname><given-names>K</given-names></name><name><surname>Michaud</surname><given-names>K</given-names></name><name><surname>Araujo</surname><given-names>AB</given-names></name></person-group><fpage>1551</fpage><lpage>1557</lpage><volume>37</volume><year>2017</year><pub-id pub-id-type="pmid">28455559</pub-id></element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years</article-title><source>Ann Rheum Dis</source><person-group><name><surname>Turesson</surname><given-names>C</given-names></name><name><surname>O'Fallon</surname><given-names>WM</given-names></name><name><surname>Crowson</surname><given-names>CS</given-names></name><name><surname>Gabriel</surname><given-names>SE</given-names></name><name><surname>Matteson</surname><given-names>EL</given-names></name></person-group><fpage>722</fpage><lpage>727</lpage><volume>62</volume><year>2003</year><pub-id pub-id-type="pmid">12860726</pub-id></element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis</article-title><source>Nat Genet</source><person-group><name><surname>van der Woude</surname><given-names>D</given-names></name><name><surname>Alemayehu</surname><given-names>WG</given-names></name><name><surname>Verduijn</surname><given-names>W</given-names></name><name><surname>de Vries</surname><given-names>RR</given-names></name><name><surname>Houwing-Duistermaat</surname><given-names>JJ</given-names></name><name><surname>Huizinga</surname><given-names>TW</given-names></name><name><surname>Toes</surname><given-names>RE</given-names></name></person-group><fpage>814</fpage><lpage>816</lpage><volume>42</volume><year>2010</year><pub-id pub-id-type="pmid">20877316</pub-id></element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Intestinal dysbiosis and rheumatoid arthritis: a link between gut microbiota and the pathogenesis of rheumatoid arthritis</article-title><source>J Immunol Res</source><person-group><name><surname>Horta-Baas</surname><given-names>G</given-names></name><name><surname>Romero-Figueroa</surname><given-names>MDS</given-names></name><name><surname>Montiel-Jarquín</surname><given-names>AJ</given-names></name><name><surname>Pizano-Zárate</surname><given-names>ML</given-names></name><name><surname>García-Mena</surname><given-names>J</given-names></name><name><surname>Ramírez-Durán</surname><given-names>N</given-names></name></person-group><fpage>4835189</fpage><volume>2017</volume><year>2017</year><pub-id pub-id-type="pmid">28948174</pub-id></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Defining the proteomic landscape of rheumatoid arthritis: progress and prospective clinical applications</article-title><source>Expert Rev Proteomics</source><person-group><name><surname>Lourido</surname><given-names>L</given-names></name><name><surname>Blanco</surname><given-names>FJ</given-names></name><name><surname>Ruiz-Romero</surname><given-names>C</given-names></name></person-group><fpage>431</fpage><lpage>444</lpage><volume>14</volume><year>2017</year><pub-id pub-id-type="pmid">28425787</pub-id></element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>The lung microbiota in early rheumatoid arthritis and autoimmunity</article-title><source>Microbiome</source><person-group><name><surname>Scher</surname><given-names>JU</given-names></name><name><surname>Joshua</surname><given-names>V</given-names></name><name><surname>Artacho</surname><given-names>A</given-names></name><etal></etal></person-group><fpage>60</fpage><volume>4</volume><year>2016</year><pub-id pub-id-type="pmid">27855721</pub-id></element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Proteome analysis of rheumatoid arthritis gut mucosa</article-title><source>J Proteome Res</source><person-group><name><surname>Bennike</surname><given-names>TB</given-names></name><name><surname>Ellingsen</surname><given-names>T</given-names></name><name><surname>Glerup</surname><given-names>H</given-names></name><etal></etal></person-group><fpage>346</fpage><lpage>354</lpage><volume>16</volume><year>2017</year><pub-id pub-id-type="pmid">27627584</pub-id></element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis</article-title><source>Elife</source><person-group><name><surname>Scher</surname><given-names>JU</given-names></name><name><surname>Sczesnak</surname><given-names>A</given-names></name><name><surname>Longman</surname><given-names>RS</given-names></name><etal></etal></person-group><fpage>0</fpage><volume>2</volume><year>2013</year></element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Periodontal disease and the oral microbiota in new‐onset rheumatoid arthritis</article-title><source>Arthritis Rheum</source><person-group><name><surname>Scher</surname><given-names>JU</given-names></name><name><surname>Ubeda</surname><given-names>C</given-names></name><name><surname>Equinda</surname><given-names>M</given-names></name><etal></etal></person-group><fpage>3083</fpage><lpage>3094</lpage><volume>64</volume><year>2012</year><pub-id pub-id-type="pmid">22576262</pub-id></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis</article-title><source>Int Immunopharmacol</source><person-group><name><surname>Mikuls</surname><given-names>TR</given-names></name><name><surname>Payne</surname><given-names>JB</given-names></name><name><surname>Reinhardt</surname><given-names>RA</given-names></name><etal></etal></person-group><fpage>38</fpage><lpage>42</lpage><volume>9</volume><year>2009</year><pub-id pub-id-type="pmid">18848647</pub-id></element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study</article-title><source>Arthritis Res Ther</source><person-group><name><surname>de Smit</surname><given-names>M</given-names></name><name><surname>Westra</surname><given-names>J</given-names></name><name><surname>Vissink</surname><given-names>A</given-names></name><name><surname>Doornbos-van der Meer</surname><given-names>B</given-names></name><name><surname>Brouwer</surname><given-names>E</given-names></name><name><surname>van Winkelhoff</surname><given-names>AJ</given-names></name></person-group><fpage>0</fpage><volume>14</volume><year>2012</year></element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>Periodontal disease and periodontal bacteria as triggers for rheumatoid arthritis</article-title><source>Best Prac Res Clin Rheum</source><person-group><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Meade</surname><given-names>J</given-names></name><name><surname>Mankia</surname><given-names>K</given-names></name><name><surname>Emery</surname><given-names>P</given-names></name><name><surname>Devine</surname><given-names>DA</given-names></name></person-group><fpage>19</fpage><lpage>30</lpage><volume>31</volume><year>2017</year></element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>The microbiome and rheumatoid arthritis</article-title><source>Nat Rev Rheumatol</source><person-group><name><surname>Scher</surname><given-names>JU</given-names></name><name><surname>Abramson</surname><given-names>SB</given-names></name></person-group><fpage>569</fpage><lpage>578</lpage><volume>7</volume><year>2011</year><pub-id pub-id-type="pmid">21862983</pub-id></element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>The biology and underlying mechanisms of cross-presentation of exogenous antigens on MHC-I molecules</article-title><source>Annu Rev Immunol</source><person-group><name><surname>Cruz</surname><given-names>FM</given-names></name><name><surname>Colbert</surname><given-names>JD</given-names></name><name><surname>Merino</surname><given-names>E</given-names></name><name><surname>Kriegsman</surname><given-names>BA</given-names></name><name><surname>Rock</surname><given-names>KL</given-names></name></person-group><fpage>149</fpage><lpage>176</lpage><volume>35</volume><year>2017</year><pub-id pub-id-type="pmid">28125356</pub-id></element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis</article-title><source>Ci Ji Yi Xue Za Zhi</source><person-group><name><surname>Yu</surname><given-names>HC</given-names></name><name><surname>Lu</surname><given-names>MC</given-names></name></person-group><fpage>5</fpage><lpage>10</lpage><volume>31</volume><year>2019</year><pub-id pub-id-type="pmid">30692825</pub-id></element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide</article-title><source>Arthritis Rheum</source><person-group><name><surname>Schellekens</surname><given-names>GA</given-names></name><name><surname>Visser</surname><given-names>H</given-names></name><name><surname>de Jong</surname><given-names>BA</given-names></name><name><surname>van den Hoogen</surname><given-names>FH</given-names></name><name><surname>Hazes</surname><given-names>JM</given-names></name><name><surname>Breedveld</surname><given-names>FC</given-names></name><name><surname>van Venrooij</surname><given-names>WJ</given-names></name></person-group><fpage>155</fpage><lpage>163</lpage><volume>43</volume><year>2000</year><pub-id pub-id-type="pmid">10643712</pub-id></element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Neonatal mucosal immunology</article-title><source>Mucosal Immunol</source><person-group><name><surname>Torow</surname><given-names>N</given-names></name><name><surname>Marsland</surname><given-names>BJ</given-names></name><name><surname>Hornef</surname><given-names>MW</given-names></name><name><surname>Gollwitzer</surname><given-names>ES</given-names></name></person-group><fpage>5</fpage><lpage>17</lpage><volume>10</volume><year>2017</year><pub-id pub-id-type="pmid">27649929</pub-id></element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>Streptococcal cell wall‐induced polyarthritis in the rat: mechanisms for chronicity and regulation of susceptibility</article-title><source>APMIS</source><person-group><name><surname>van den Broek</surname><given-names>MF</given-names></name></person-group><fpage>861</fpage><lpage>878</lpage><volume>97</volume><year>1989</year><pub-id pub-id-type="pmid">2679806</pub-id></element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>Polyarthritis in rats following the systemic injection of Lactobacillus casei cell walls in aqueous suspension</article-title><source>Arthritis Rheum</source><person-group><name><surname>Lehman</surname><given-names>TJ</given-names></name><name><surname>Allen</surname><given-names>JB</given-names></name><name><surname>Plotz</surname><given-names>PH</given-names></name><name><surname>Wilder</surname><given-names>RL</given-names></name></person-group><fpage>1259</fpage><lpage>1265</lpage><volume>26</volume><year>1983</year><pub-id pub-id-type="pmid">6414486</pub-id></element-citation></ref><ref id="REF21"><label>21</label><element-citation publication-type="journal"><article-title>Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells</article-title><source>Immunity</source><person-group><name><surname>Wu</surname><given-names>HJ</given-names></name><name><surname>Ivanov</surname><given-names>II</given-names></name><name><surname>Darce</surname><given-names>J</given-names></name><etal></etal></person-group><fpage>815</fpage><lpage>827</lpage><volume>32</volume><year>2010</year><pub-id pub-id-type="pmid">20620945</pub-id></element-citation></ref><ref id="REF22"><label>22</label><element-citation publication-type="journal"><article-title>Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine</article-title><source>Arthritis Rheumatol</source><person-group><name><surname>Maeda</surname><given-names>Y</given-names></name><name><surname>Kurakawa</surname><given-names>T</given-names></name><name><surname>Umemoto</surname><given-names>E</given-names></name><etal></etal></person-group><fpage>2646</fpage><lpage>2661</lpage><volume>68</volume><year>2016</year><pub-id pub-id-type="pmid">27333153</pub-id></element-citation></ref><ref id="REF23"><label>23</label><element-citation publication-type="journal"><article-title>Cigarette smoking and autoimmune disease: what can we learn from epidemiology?</article-title><source>Lupus</source><person-group><name><surname>Costenbader</surname><given-names>KH</given-names></name><name><surname>Karlson</surname><given-names>EW</given-names></name></person-group><fpage>737</fpage><lpage>745</lpage><volume>15</volume><year>2006</year><pub-id pub-id-type="pmid">17153844</pub-id></element-citation></ref><ref id="REF24"><label>24</label><element-citation publication-type="journal"><article-title>Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase</article-title><source>Infect Immun</source><person-group><name><surname>McGraw</surname><given-names>WT</given-names></name><name><surname>Potempa</surname><given-names>J</given-names></name><name><surname>Farley</surname><given-names>D</given-names></name><name><surname>Travis</surname><given-names>J</given-names></name></person-group><fpage>3248</fpage><lpage>3256</lpage><volume>67</volume><year>1999</year><pub-id pub-id-type="pmid">10377098</pub-id></element-citation></ref><ref id="REF25"><label>25</label><element-citation publication-type="journal"><article-title>Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis</article-title><source>Sci Transl Med</source><person-group><name><surname>Konig</surname><given-names>MF</given-names></name><name><surname>Abusleme</surname><given-names>L</given-names></name><name><surname>Reinholdt</surname><given-names>J</given-names></name><etal></etal></person-group><fpage>369</fpage><volume>8</volume><year>2016</year></element-citation></ref><ref id="REF26"><label>26</label><element-citation publication-type="journal"><article-title>Linkages between oral commensal bacteria and atherosclerotic plaques in coronary artery disease patients</article-title><source>NPJ Biofilms Microbiomes</source><person-group><name><surname>Chhibber-Goel</surname><given-names>J</given-names></name><name><surname>Singhal</surname><given-names>V</given-names></name><name><surname>Bhowmik</surname><given-names>D</given-names></name><name><surname>Vivek</surname><given-names>R</given-names></name><name><surname>Parakh</surname><given-names>N</given-names></name><name><surname>Bhargava</surname><given-names>B</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name></person-group><fpage>7</fpage><volume>2</volume><year>2016</year><pub-id pub-id-type="pmid">28649401</pub-id></element-citation></ref><ref id="REF27"><label>27</label><element-citation publication-type="journal"><article-title>Progression on citrullination of proteins in gastrointestinal cancers</article-title><source>Front Oncol</source><person-group><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name></person-group><fpage>15</fpage><volume>9</volume><year>2019</year><pub-id pub-id-type="pmid">30740359</pub-id></element-citation></ref><ref id="REF28"><label>28</label><element-citation publication-type="journal"><article-title>Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance</article-title><source>Microbiol Mol Biol Rev</source><person-group><name><surname>Chopra</surname><given-names>I</given-names></name><name><surname>Roberts</surname><given-names>M</given-names></name></person-group><fpage>232</fpage><lpage>260</lpage><volume>65</volume><year>2001</year><pub-id pub-id-type="pmid">11381101</pub-id></element-citation></ref><ref id="REF29"><label>29</label><element-citation publication-type="journal"><article-title>Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines</article-title><source>J Antimicrob Chemother</source><person-group><name><surname>Agwuh</surname><given-names>KN</given-names></name><name><surname>MacGowan</surname><given-names>A</given-names></name></person-group><fpage>256</fpage><lpage>265</lpage><volume>58</volume><year>2006</year><pub-id pub-id-type="pmid">16816396</pub-id></element-citation></ref><ref id="REF30"><label>30</label><element-citation publication-type="journal"><article-title>Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline</article-title><source>Biochem Pharmacol</source><person-group><name><surname>Pruzanski</surname><given-names>W</given-names></name><name><surname>Greenwald</surname><given-names>RA</given-names></name><name><surname>Street</surname><given-names>LP</given-names></name><name><surname>Laliberte</surname><given-names>F</given-names></name><name><surname>Stefanski</surname><given-names>E</given-names></name><name><surname>Vadas</surname><given-names>P</given-names></name></person-group><fpage>1165</fpage><lpage>1170</lpage><volume>44</volume><year>1992</year><pub-id pub-id-type="pmid">1417938</pub-id></element-citation></ref><ref id="REF31"><label>31</label><element-citation publication-type="journal"><article-title>Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage</article-title><source>J Rheumatol</source><person-group><name><surname>Greenwald</surname><given-names>RA</given-names></name><name><surname>Moak</surname><given-names>SA</given-names></name><name><surname>Ramamurthy</surname><given-names>NS</given-names></name><name><surname>Golub</surname><given-names>LM</given-names></name></person-group><fpage>927</fpage><lpage>938</lpage><volume>19</volume><year>1992</year><uri xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/1404131">http://www.ncbi.nlm.nih.gov/pubmed/1404131</uri><pub-id pub-id-type="pmid">1404131</pub-id></element-citation></ref><ref id="REF32"><label>32</label><element-citation publication-type="journal"><article-title>Scavenging of hypochlorous acid by tetracycline, rifampicin and some other antibiotics: a possible antioxidant action of rifampicin and tetracycline?</article-title><source>Biochem Pharmacol</source><person-group><name><surname>Wasil</surname><given-names>M</given-names></name><name><surname>Halliwell</surname><given-names>B</given-names></name><name><surname>Moorhouse</surname><given-names>CP</given-names></name></person-group><fpage>775</fpage><lpage>778</lpage><volume>37</volume><year>1988</year><pub-id pub-id-type="pmid">2829926</pub-id></element-citation></ref><ref id="REF33"><label>33</label><element-citation publication-type="journal"><article-title>Minocycline in active rheumatoid arthritis</article-title><source>Arthritis Rheum</source><person-group><name><surname>Kloppenburg</surname><given-names>M</given-names></name><name><surname>Breedveld</surname><given-names>FC</given-names></name><name><surname>Terwiel</surname><given-names>JP</given-names></name><name><surname>Mallee</surname><given-names>C</given-names></name><name><surname>Dijkmans</surname><given-names>BA</given-names></name></person-group><fpage>629</fpage><lpage>636</lpage><volume>37</volume><year>1994</year><pub-id pub-id-type="pmid">8185689</pub-id></element-citation></ref><ref id="REF34"><label>34</label><element-citation publication-type="journal"><article-title>Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial</article-title><source>Ann Intern Med</source><person-group><name><surname>Tilley</surname><given-names>BC</given-names></name><name><surname>Alarcón</surname><given-names>GS</given-names></name><name><surname>Heyse</surname><given-names>SP</given-names></name><etal></etal></person-group><fpage>81</fpage><lpage>89</lpage><volume>122</volume><year>1995</year><pub-id pub-id-type="pmid">7993000</pub-id></element-citation></ref><ref id="REF35"><label>35</label><element-citation publication-type="journal"><article-title>Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial</article-title><source>Arthritis Rheum</source><person-group><name><surname>O'Dell</surname><given-names>JR</given-names></name><name><surname>Haire</surname><given-names>CE</given-names></name><name><surname>Palmer</surname><given-names>W</given-names></name><etal></etal></person-group><fpage>842</fpage><lpage>848</lpage><volume>40</volume><year>1997</year><pub-id pub-id-type="pmid">9153544</pub-id></element-citation></ref><ref id="REF36"><label>36</label><element-citation publication-type="journal"><article-title>Treatment of early seropositive rheumatoid arthritis: a two‐year, double‐blind comparison of minocycline and hydroxychloroquine</article-title><source>Arthritis Rheum</source><person-group><name><surname>O'Dell</surname><given-names>JR</given-names></name><name><surname>Blakely</surname><given-names>KW</given-names></name><name><surname>Mallek</surname><given-names>JA</given-names></name><etal></etal></person-group><fpage>2235</fpage><lpage>2241</lpage><volume>44</volume><year>2001</year><pub-id pub-id-type="pmid">11665963</pub-id></element-citation></ref><ref id="REF37"><label>37</label><element-citation publication-type="journal"><article-title>Treatment of resistant rheumatoid arthritis with minocycline: an open study</article-title><source>J Rheumatol</source><person-group><name><surname>Langevitz</surname><given-names>P</given-names></name><name><surname>Bank</surname><given-names>I</given-names></name><name><surname>Zemer</surname><given-names>D</given-names></name><name><surname>Book</surname><given-names>M</given-names></name><name><surname>Pras</surname><given-names>M</given-names></name></person-group><fpage>1502</fpage><lpage>1504</lpage><volume>19</volume><year>1992</year><uri xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/1334514">http://www.ncbi.nlm.nih.gov/pubmed/1334514</uri><pub-id pub-id-type="pmid">1334514</pub-id></element-citation></ref><ref id="REF38"><label>38</label><element-citation publication-type="journal"><article-title>Minocycline treatment for rheumatoid arthritis: an open dose finding study</article-title><source>J Rheumatol</source><person-group><name><surname>Breedveld</surname><given-names>FC</given-names></name><name><surname>Dijkmans</surname><given-names>BA</given-names></name><name><surname>Mattie</surname><given-names>H</given-names></name></person-group><fpage>43</fpage><lpage>46</lpage><volume>17</volume><year>1990</year><uri xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/2313671">http://www.ncbi.nlm.nih.gov/pubmed/2313671</uri><pub-id pub-id-type="pmid">2313671</pub-id></element-citation></ref><ref id="REF39"><label>39</label><element-citation publication-type="journal"><article-title>Tetracycline in the treatment of rheumatoid arthritis. A double blind controlled study</article-title><source>Arthritis Rheum</source><person-group><name><surname>Skinner</surname><given-names>M</given-names></name><name><surname>Cathcart</surname><given-names>ES</given-names></name><name><surname>Mills</surname><given-names>JA</given-names></name><name><surname>Pinals</surname><given-names>RS</given-names></name></person-group><fpage>727</fpage><lpage>732</lpage><volume>14</volume><year>1971</year><pub-id pub-id-type="pmid">4944432</pub-id></element-citation></ref><ref id="REF40"><label>40</label><element-citation publication-type="journal"><article-title>Lack of effect of doxycycline on disease activity and joint damage in patients with rheumatoid arthritis. A double blind, placebo controlled trial </article-title><source>J Rheumatol</source><person-group><name><surname>van der Laan</surname><given-names>W</given-names></name><name><surname>Molenaar</surname><given-names>E</given-names></name><name><surname>Ronday</surname><given-names>K</given-names></name><etal></etal></person-group><fpage>1967</fpage><lpage>1974</lpage><volume>28</volume><year>2001</year><uri xlink:href="http://www.jrheum.org/content/28/9/1967">http://www.jrheum.org/content/28/9/1967</uri><pub-id pub-id-type="pmid">11550961</pub-id></element-citation></ref><ref id="REF41"><label>41</label><element-citation publication-type="journal"><article-title>Pilot clinical trial of intravenous doxycycline versus placebo for rheumatoid arthritis</article-title><source>J Rheumatol</source><person-group><name><surname>Pillemer</surname><given-names>S</given-names></name><name><surname>Gulko</surname><given-names>P</given-names></name><name><surname>Ligier</surname><given-names>S</given-names></name><etal></etal></person-group><fpage>41</fpage><lpage>43</lpage><volume>30</volume><year>2003</year><uri xlink:href="http://www.jrheum.org/content/30/1/41.long">http://www.jrheum.org/content/30/1/41.long</uri><pub-id pub-id-type="pmid">12508388</pub-id></element-citation></ref><ref id="REF42"><label>42</label><element-citation publication-type="journal"><article-title>The effects of intravenous doxycycline therapy for rheumatoid arthritis: a randomized, double‐blind, placebo‐controlled trial</article-title><source>Arthritis Rheum</source><person-group><name><surname>St. Clair</surname><given-names>EW</given-names></name><name><surname>Wilkinson</surname><given-names>WE</given-names></name><name><surname>Pisetsky</surname><given-names>DS</given-names></name><name><surname>Sexton</surname><given-names>DJ</given-names></name><name><surname>Drew</surname><given-names>R</given-names></name><name><surname>Kraus</surname><given-names>VB</given-names></name><name><surname>Greenwald</surname><given-names>RA</given-names></name></person-group><fpage>1043</fpage><lpage>1047</lpage><volume>44</volume><year>2001</year><pub-id pub-id-type="pmid">11357896</pub-id></element-citation></ref><ref id="REF43"><label>43</label><element-citation publication-type="journal"><article-title>Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity</article-title><source>J Rheumatol</source><person-group><name><surname>Stone</surname><given-names>M</given-names></name><name><surname>Fortin</surname><given-names>PR</given-names></name><name><surname>Pacheco-Tena</surname><given-names>C</given-names></name><name><surname>Inman</surname><given-names>RD</given-names></name></person-group><fpage>2112</fpage><lpage>2122</lpage><volume>30</volume><year>2003</year><uri xlink:href="http://www.jrheum.org/content/30/10/2112.long">http://www.jrheum.org/content/30/10/2112.long</uri><pub-id pub-id-type="pmid">14528503</pub-id></element-citation></ref><ref id="REF44"><label>44</label><element-citation publication-type="journal"><article-title>Rheumatoid arthritis-associated autoimmunity due to aggregatibacter actinomycetemcomitans and its resolution with antibiotic therapy</article-title><source>Front Immunol</source><person-group><name><surname>Mukherjee</surname><given-names>A</given-names></name><name><surname>Jantsch</surname><given-names>V</given-names></name><name><surname>Khan</surname><given-names>R</given-names></name><etal></etal></person-group><fpage>2352</fpage><volume>9</volume><year>2018</year><pub-id pub-id-type="pmid">30459755</pub-id></element-citation></ref><ref id="REF45"><label>45</label><element-citation publication-type="journal"><article-title>Antibiotic susceptibility of Aggregatibacter actinomycetemcomitans JP2 in a biofilm</article-title><source>J Oral Microbiol</source><person-group><name><surname>Oettinger-Barak</surname><given-names>O</given-names></name><name><surname>Dashper</surname><given-names>SG</given-names></name><name><surname>Catmull</surname><given-names>DV</given-names></name><name><surname>Adams</surname><given-names>GG</given-names></name><name><surname>Sela</surname><given-names>MN</given-names></name><name><surname>Machtei</surname><given-names>EE</given-names></name><name><surname>Reynolds</surname><given-names>EC</given-names></name></person-group><fpage>20320</fpage><volume>5</volume><year>2013</year></element-citation></ref><ref id="REF46"><label>46</label><element-citation publication-type="journal"><article-title>Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects</article-title><source>Arthritis Res Ther</source><person-group><name><surname>Smith</surname><given-names>CJ</given-names></name><name><surname>Sayles</surname><given-names>H</given-names></name><name><surname>Mikuls</surname><given-names>TR</given-names></name><name><surname>Michaud</surname><given-names>K</given-names></name></person-group><fpage>0</fpage><volume>13</volume><year>2011</year></element-citation></ref><ref id="REF47"><label>47</label><element-citation publication-type="journal"><article-title>Minocycline-induced autoimmune syndromes: an overview</article-title><source>Semin Arthritis Rheum</source><person-group><name><surname>Elkayam</surname><given-names>O</given-names></name><name><surname>Yaron</surname><given-names>M</given-names></name><name><surname>Caspi</surname><given-names>D</given-names></name></person-group><fpage>392</fpage><lpage>397</lpage><volume>28</volume><year>1999</year><pub-id pub-id-type="pmid">10406406</pub-id></element-citation></ref><ref id="REF48"><label>48</label><element-citation publication-type="journal"><article-title>Low risk of primary Clostridium difficile infection with tetracyclines: a systematic review and metaanalysis</article-title><source>Clin Infect Dis</source><person-group><name><surname>Tariq</surname><given-names>R</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Kapoor</surname><given-names>S</given-names></name><name><surname>Orenstein</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Pardi</surname><given-names>DS</given-names></name><name><surname>Khanna</surname><given-names>S</given-names></name></person-group><fpage>514</fpage><lpage>522</lpage><volume>66</volume><year>2018</year><pub-id pub-id-type="pmid">29401273</pub-id></element-citation></ref><ref id="REF49"><label>49</label><element-citation publication-type="journal"><article-title>Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women</article-title><source>Cancer Epidemiol Biomarkers Prev</source><person-group><name><surname>Friedman</surname><given-names>GD</given-names></name><name><surname>Oestreicher</surname><given-names>N</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Quesenberry CP</surname><given-names>Jr</given-names></name><name><surname>Udaltsova</surname><given-names>N</given-names></name><name><surname>Habel</surname><given-names>LA</given-names></name></person-group><fpage>2102</fpage><lpage>2106</lpage><volume>15</volume><year>2006</year><pub-id pub-id-type="pmid">17119034</pub-id></element-citation></ref><ref id="REF50"><label>50</label><element-citation publication-type="journal"><article-title>Recurrent antibiotic exposure may promote cancer formation--another step in understanding the role of the human microbiota?</article-title><source>Eur J Cancer</source><person-group><name><surname>Boursi</surname><given-names>B</given-names></name><name><surname>Mamtani</surname><given-names>R</given-names></name><name><surname>Haynes</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>YX</given-names></name></person-group><fpage>2655</fpage><lpage>2664</lpage><volume>51</volume><year>2015</year><pub-id pub-id-type="pmid">26338196</pub-id></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000939 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000939 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:6783212
|texte= Reconsidering the Use of Minocycline in the Preliminary Treatment Regime of Rheumatoid Arthritis
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:31608186" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |